Search for Clinical Trial Results

Sponsored By

Leukemia, Myelomonocytic, Acute - 25 Studies Found

Status Study
Completed Study Name: Study of XIAP Antisense Given With Chemotherapy for Refractory/Relapsed AML
Condition: Leukemia, Myelomonocytic, Acute
Date: 2006-08-10
Interventions: Drug: XIAP antisense 2 days loading dose followed by weekly 2hr infusion
Completed Study Name: Pilot Study of Erlotinib for the Treatment of Patients With de Novo Acute Myeloid Leukemia
Condition: Leukemia, Myelomonocytic, Acute
Date: 2010-07-30
Interventions: Drug: Erlotinib Erlotinib will be administered orally at 150 mg once a day, continuously. Each cycle wil
Withdrawn Study Name: A Study of Volasertib Plus Induction Chemotherapy for Acute Myeloid Leukemia
Condition:
  • Leukemia, Myeloid, Acute
  • Leukemia, Monocytic, Acute
  • Date: 2015-07-06
    Interventions:
    • Drug: Volasertib Addition of s
Completed Study Name: Studying Biomarkers in Samples From Younger Patients With Acute Myeloid Leukemia
Condition:
  • Childhood Acute Monoblastic Leukemia (M5a)
  • Childhood Acute Monocytic Leukemia (M5b)
    • Date: 2012-07-13
    Interventions: Other: laboratory biomarker analysis Correlative studies
Recruiting Study Name: A Study of HDC/IL-2 Treatment in Chronic Myelomonocytic Leukemia (CMML)
Condition: Leukemia, Myelomonocytic, Chronic
Date: 2017-01-24
Interventions:
  • Drug: Cohort 1, Ceplene® and Proleukin®

Recruiting Study Name: Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia
Condition: Leukemia, Myelomonocytic, Chronic
Date: 2016-06-15
Interventions: Drug: Tipifarnib Oral tablet Other Names:
Recruiting Study Name: Study of Lenzilumab (KB003) in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML)
Condition: Chronic Myelomonocytic Leukemia (CMML)
Date: 2015-08-27
Interventions: Drug: lenzilumab Other Names:
  • KB003
  • Monoclonal Antibody
Active, not recruiting Study Name: A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib
Condition: Myelomonocytic Leukemia
Date: 2013-01-24
Interventions: Drug: Ruxolitinib In Phase I, participants will be allocated to twice a day (BID) doses of 10 mg/d up to
Active, not recruiting Study Name: Lenalidomide in Patients With Chronic Myelomonocytic Leukemia
Condition: Chronic Myelomonocytic Leukemia
Date: 2011-05-09
Interventions: Drug: Revlimid Dose escalation 5mg - 10mg - 15mg - 20mg in
Completed Study Name: A Study of 5-Azacitidine (Vidaza®) in Patients With Chronic Myelomonocytic Leukemia
Condition: Chronic Myelomonocytic Leukemia
Date: 2011-04-29
Interventions: Drug: 5-Azacitidine Administered on Days 1-7 of each Cycle
Next >>>